Boehringer Ingelheim finalizes acquisition of AMGENs Fremont facility in the USA
Ingelheim, Germany (25 March 2011)
– Yesterday Boehringer Ingelheim formally acquired
Amgen’s biopharmaceutical development and manufacturing
facility in Fremont, California (USA). This acquisition involves
leasing buildings, acquiring physical equipment and assuming
manufacturing processes done at the Fremont site. The
state-of-the-art facility currently employs more than 300 employees
and consists of more than 200,000 square feet for laboratories,
manufacturing and process development suitable for clinical and
market supplies. The purchase agreement was signed in January 2011.
The companies agreed not to disclose details of the purchase
"Presence in Fremont, CA aligns with our growth strategy in several ways," said Simon Sturge, Corporate Senior Vice President Biopharmaceuticals, Boehringer Ingelheim GmbH. "The strategic decision to have a state–of-the-art contract manufacturing facility in the U.S. Bay Area biotechnology cluster will give Boehringer Ingelheim a greater opportunity to serve current and future customers. In addition the technological expertise present at Fremont will complement our goal to further increase Boehringer Ingelheim’s world leading position in the process development and manufacture of biopharmaceuticals."